Cocrystallization of the anticancer drug 5-fluorouracil and coformers urea, thiourea or pyrazinamide using supercritical CO2 as an antisolvent (SAS) and as a solvent (CSS)
Graphical abstract
Introduction
5-Fluorouracil (5-Fu) is a well-known drug used in chemotherapy for the treatment of cancer. 5-Fu is a class III drug according to the biopharmaceutics classification system (BCS), i.e., high solubility and low permeability. There are two distinctive 5-Fu polymorphs known; polymorph I [1] (triclinic) and polymorph II [2] (monoclinic). Due to its antimetabolite action, 5-Fu is one of the most commonly used drugs to treat a wide range of cancers, including head and neck cancer [3], some skin cancers [4], and breast cancer [5]. It is though in colorectal cancer where 5-Fu has demonstrated a higher impact with increased overall and disease-free survival of patients undergoing chemotherapy [6]. Nevertheless, response rates to 5-Fu based chemotherapy are relatively low (10–15 %) in advanced colorectal cancer [6], and although they improve in combined chemotherapies (40–50 % [7]) there is still a need to overcome its main drawbacks such as tumours developing resistance, lack of selectivity, toxicity and effectiveness (more than 80 % of the administered 5-Fu catabolizes in the liver limiting its bioavailability in normal and tumour cells).
The main research paths that have been taken to improve the performance of 5-Fu are polychemeotherapy [8], identification of the pathways that are involved in tumour cell response to 5-Fu [9], development of 5-Fu derivatives [10], development of enhanced drug delivery systems [11] and enhancement of bioavailability and physicochemical properties of 5-Fu through cocrystalization [[12], [13], [14], [15], [16], [17], [18], [19], [20]]. The latter path is the one chosen in this work.
Supercritical fluid technology has been mainly employed in the 5-Fu micronization and the development of novel, enhanced delivery systems for 5-Fu. The techniques and achievements that have been accomplished in this field with the aid of supercritical fluids are outlined next.
Supercritical CO2 has been used by several authors to impregnate 5-Fu to polymers. First reported studies are those of Guney and Akgerman [21]. These authors achieved a controlled release of the drug by supercritical impregnation of 5-Fu in poly(Lactide-coGlycolide) (PLGA). Cabezas et al. [22,23] used supercritical CO2 to foam a polymeric support of poly(D,L-lactide) and PLGA, and simultaneously impregnate it with 5-Fu. A similar technique was used by Salerno et al. [24,25] to impregnate polycaprolactone achieving a 5-Fu progressive release over six days. Hao et al. [26] used supercritical carbon dioxide to entrap 5-Fu into a mesocellular silica foam modified with thermal and pH functional groups.
Many authors have used CO2 as an antisolvent to produce enhanced 5-Fu formulations. The solution enhanced dispersion by supercritical fluids (SEDS) technique was employed by Chen et al. [27] to prepare microparticles of 5-Fu and poly (L-lactide) (PLLA). These authors also used the SEDS technology to prepare 5-Fu-SiO2-PLLA microcapsules [28]. A “reverse emulsion-SEDS” technique was employed by Zhang et al. [29] to prepare nanoparticles of 5-Fu-PLLA-polyethylene glycol. The gas antisolvent (GAS) and supercritical antisolvent (SAS) techniques have also been explored. Kalantarian et al. [30] produced partly spherical 5-Fu nanoparticles using the SAS technique. The same authors used the GAS and SAS techniques to produce coprecipitates of 5-Fu and PLGA [31] accomplishing long term release profiles with partial burst effect. The SAS technique combined with the supercritical impregnation was used by Zhan et al. [32] to generate 5-Fu loaded microparticles of PLLA. The GAS technique was used by Esfandiari and Ghoreishi [33,34] to micronize 5-Fu. Our research group has also used the SAS technique to micronize 5-Fu and to prepare a 5-Fu-PLLA composite [11]. The produced composite presented a controlled drug delivery with a much slower release rate compared to the pure drug.
Although several supercritical techniques have been employed in the production of enhanced 5-Fu formulations, none of them has been used to prepare 5-Fu co-crystals. Cocrystals generate great interest in the pharmaceutical industry as they present a path to improve the overall bioavailability and performance of an active pharmaceutical ingredient (API) [35]. A pharmaceutical co-crystal is formed by an API and a suitable coformer or another API. Both co-crystal components form a supramolecular crystal structure through a non-covalent bond. By choosing the right coformer the properties of the API may be tuned improving the drug dissolution rate, its thermal stability, hygroscopicity, mechanical and even organoleptic properties [36]. Several authors have obtained different co-crystals of 5-Fu by conventional methods [[12], [13], [14], [15], [16], [17], [18], [19], [20],37]
The use of conventional methods in the co-crystal preparation presents several drawbacks such as scaling-up difficulties or the presence of homocrystals in the final product and often require post purification steps to eliminate solvents. The SAS precipitation has been shown to overcome the difficulties associated to these methods [[38], [39], [40]]. In this study, the feasibility of the SAS technique in producing co-crystals of 5-Fu with the coformers urea, thiourea, or PZA was investigated. The production of these co-crystals was also attempted through cocrystallization with supercritical solvent (CSS) in order to compare both supercritical techniques. In the SAS technique CO2 plays the role of the antisolvent while in the CSS technique CO2 plays the role of the solvent. Padrela et al. [41] and Ribas et al. [42] have successfully prepared co-crystals via CSS. The molecular structures of the polymorphs of 5-Fu [1,2], urea [43], thiourea [44] and PZA [45] involved in this study and those of the 5-Fu-urea [18] and 5-Fu-thiourea [18] co-crystals are given in Fig. 1.
Amides such as PZA are often used as coformers of pharmaceutical co-crystals [46]. PZA is an antituberculosis drug that has been used as a coformer with the anti-inflammatory drug diflunisal [47]. The 5-Fu-PZA co-crystal is a combination drug with great potential in a dual therapy. Urea and thiourea are also considered good coformers as they can easily form molecular complexes in the solid state. The NH2 hydrogen atoms act as donors in hydrogen bonding while the lone pairs on the carbonyl oxygen atom act as acceptors. Furthermore, the pharmacological activity of urea and thiourea derivatives as antimicrobial and anticancer drugs and the anticancer potential of 5-Fu-urea and 5-Fu-thiourea co-crystals have been explored [18,48].
Section snippets
Materials
Experiments using the SAS technique were performed at Universidad Complutense de Madrid (UCM) and the following materials were employed: CO2 (Air Liquide 99.98 mol % pure), 5-fluorouracil (5-Fu, Sigma-Aldrich, ≥ 99 mol % pure), urea (Sigma-Aldrich, ≥ 99 mol % pure), thiourea (Sigma-Aldrich, ≥ 99 mol % pure), pyrazinamide (PZA, Sigma-Aldrich, ≥ 99 mol % pure), acetone (Fischer chemical, ≥ 99.9 mol % pure), dichloromethane (Sigma-Aldrich, ≥ 99.9 mol % pure), ethanol (PanReac, ≥ 99.5 mol % pure),
SAS experiments
A summary of conditions and results is presented in Table 1. Solvent selection is unquestionably an important factor that will influence not only size and morphology of the SAS precipitate but also its polymorphic outcome [35]. In previous studies carried out at our laboratory at conditions above the mixtures critical locus, temperature, pressure and solution concentration were also found to be important factors [50]. In this research though the main goal is to compare the co-crystals obtained
Conclusions
Cocrystallization of the antitumoral drug 5-Fu with three different coformers has been attempted using two different supercritical CO2 technologies, SAS and CSS, in which CO2 acts as antisolvent or solvent, respectively.
The SAS technology was able to produce co-crystals of 5-Fu with urea and thiourea. TGA and micro-elemental analysis showed that the SAS precipitates had the stoichiometric amount of the co-crystal components. However, PXRD analysis of samples 1 and 2 indicated the presence of
Declaration of Competing Interest
None.
Acknowledgments
We gratefully acknowledge the financial support through MINECO RTI2018-097230-B-I00 and UCM-Santander PR75/18-21583. I.A.C. thanks MINECO for its support through a FPI grant (BES-2014-067777) and a mobility fellowship (EEBB-I-17-12090).
References (61)
- et al.
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
Lancet
(2000) - et al.
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
Eur. J. Pharmacol.
(2009) - et al.
Preparation of 5-fluorouracil microparticles and 5-fluorouracil/poly(L-lactide) composites by a supercritical CO2 antisolvent process
J. Supercrit. Fluids
(2019) - et al.
Effect of adenosine on the supramolecular architecture and activity of 5-fluorouracil
J. Mol. Struct.
(2012) - et al.
Production of biodegradable porous scaffolds impregnated with 5-fluorouracil in supercritical CO2
J. Supercrit. Fluids
(2013) - et al.
Supercritical CO2 foamed polycaprolactone scaffolds for controlled delivery of 5-fluorouracil, nicotinamide and triflusal
Int. J. Pharm.
(2015) - et al.
PCL foamed scaffolds loaded with 5-fluorouracil anti-cancer drug prepared by an eco-friendly route
Mater. Sci. Eng. C-Mater. Biol. Appl.
(2017) - et al.
Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique
Int. J. Pharm.
(2012) - et al.
Synthesis of 5-Fluorouracil nanoparticles via supercritical gas antisolvent process
J. Supercrit. Fluids
(2013) - et al.
Polymorphism in the co-crystallization of the anticonvulsant drug carbamazepine and saccharin using supercritical CO2 as an anti-solvent
J. Supercrit. Fluids
(2018)
Pharmaceutical co-crystals of the anti-inflammatory drug diflunisal and nicotinamide obtained using supercritical CO2 as an antisolvent
J. CO2 Util.
Effect of gas pressure on the phase behaviour of organometallic compounds
J. Supercrit. Fluids
Determination of methanol/CO2 and acetonitrile/CO2 vapor-liquid phase equilibria using a variable-volume view cell
Fluid Phase Equilib.
Challenge of the supercritical antisolvent technique SAS to prepare cocrystal-pure powders of naproxen-nicotinamide
Chem. Eng. J.
Investigation of crystallization mechanisms for polymorphic and habit control from the Supercritical AntiSolvent process
J. Supercrit. Fluids
Dependence of SAS particle morphologies on the ternary phase equilibria
J. Supercrit. Fluids
PVP microparticles precipitation from acetone-ethanol mixtures using SAS process: effect of phase behavior
J. Supercrit. Fluids
Polymorphic properties of micronized mefenamic acid, nabumetone, paracetamol and tolbutamide produced by rapid expansion of supercritical solutions (RESS)
J. Supercrit. Fluids
Crystal and molecular structure of 5-Fluorouracil
Acta Crystallogr. Sect. B-Struct. Sci.
A new polymorph of 5-fluorouracil found following computational crystal structure predictions
J. Am. Chem. Soc.
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
N. Engl. J. Med.
Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin
Cancer
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up
N. Engl. J. Med.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
Lancet
5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced t cell-dependent antitumor immunity
Cancer Res.
5-Fluorouracil derivatives: a patent review (2012-2014)
Expert Opin. Ther. Pat.
Imatinib mesylate cocrystals: synthesis, screening, and preliminary characterization
Mon. Chem.
Cocrystals of 5-fluorouracil
CrystEngComm
Controlled synthesis of new 5-Fluorocytosine cocrystals based on the pK(a) rule
Cryst. Growth Des.
Synthon polymorphs of 1:1 co-crystal of 5-fluorouracil and 4-hydroxybenzoic acid: their relative stability and solvent polarity dependence of grinding outcomes
CrystEngComm
Cited by (28)
Cocrystal screening of anticancer drug p-toluenesulfonamide and preparation by supercritical antisolvent process
2024, Journal of Supercritical FluidsCocrystal formation of niclosamide and urea in supercritical CO<inf>2</inf> and impact of cosolvent
2023, Journal of Supercritical FluidsCo-crystal nanoarchitectonics as an emerging strategy in attenuating cancer: Fundamentals and applications
2023, Journal of Controlled ReleaseCitation Excerpt :Therefore, they developed co-crystals of 5-FU using a supercritical solvent method which displayed remarkable solubility than pure 5-FU. They concluded that improvement in solubility can enhance bioavailability and anticancer effectiveness [88]. In another report, co-crystals were formed between anticancer lenvatinib (LVT) and antibacterial sulfamerazine (SMZ) (LVT-SMZ co-crystals), and salicylic acid (SA; keratolytic agent) (LVT-SA) by Hong and team with intend to improve the drug's solubility, stability, and anticancer activity.
Solid-state and particle size control of pharmaceutical cocrystals using atomization-based techniques
2022, International Journal of PharmaceuticsCitation Excerpt :Despite the addition of methanol, the production of homocrystals in the CSS method is due to low solubilities of the solutes in scCO2. The co-solvent improved this as no cocrystals could be produced without it, but it is likely that higher levels of solubility in the supercritical medium would be required for the CSS method (Cuadra, 2020). A few cocrystals are known for exhibiting various polymorphic forms.
Development of natural bioactive delivery systems through pressurized fluids-modern techniques
2022, Herbal Bioactive-Based Drug Delivery Systems: Challenges and OpportunitiesSupercritical fluid (SCF)-assisted fabrication of carrier-free drugs: An eco-friendly welcome to active pharmaceutical ingredients (APIs)
2021, Advanced Drug Delivery Reviews